Back to top

A Phase I trial of a vaginal ring containing the ARV drug dapivirine and the contraceptive hormone levonorgestrel that assessed the ring’s safety as well as absorption patterns of dapivirine and different dosages of levonorgestrel in vaginal tissue and in blood. MTN-030/IPM 041, which was conducted at two U.S. sites, found the ring was well-tolerated with no safety concerns. The study represents an important first step toward developing a product for women that could both protect against HIV and prevent unintended pregnancy. (See also MTN-044 and MTN-038.)

Second early phase study of 90-day vaginal ring containing dapivirine and contraceptive shows promise as dual-purpose product for preventing both HIV and pregnancy
26-January-2021

First clinical trial of new dapivirine ring with both anti-HIV drug and contraceptive finds ring is well-tolerated with no safety concerns
24-October-2018

See Also
MTN-030/IPM 041 Protocol

MTN-030/IPM 041 Study Page

MTN begins first trial of new dapivirine ring with both anti-HIV drug and contraceptive
03-May-2017